In the 500 µg dose group 2/3 patients showed transient reductions in serum levels of HCV RNA (up to -1,5log10) and
in the same two patients T cell responses to
the vaccine lasting ≥ 1 month were activated.
In the 1500 µg dose group 3/6 patients showed transient reductions in serum levels of HCV RNA (up to -2,4log10) and in two of these three patients T cell responses to the vaccine were obtained that lasted ≥ 1 month.